<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640067</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2009-014484-39</org_study_id>
    <nct_id>NCT01640067</nct_id>
  </id_info>
  <brief_title>Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>hNSCALS</acronym>
  <official_title>Intra-spinal Cord Delivery of Human Neural Stem Cells in ALS Patients: Proposal for a Phase I Study/ Trapianto Intramidollare di Cellule Staminali Neurali Umane Come Terapia Putativa Per la SLA: Proposta di un Trial Clinico di Fase I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Santa Maria, Terni, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliero Universitaria Maggiore della Carita</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università di Padova Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Santa Maria, Terni, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary aim of the trial

        1. to verify safety and tolerability of expanded human fetal neural stem cells

        2. to verify safety and tolerability of a microsurgery human fetal neural stem cells
           transplantation model

        3. to recognize each change in patient's quality of life

      Secondary aim of the trial

        1. assessment of the impact of human neural stem cells transplantation on the disability of
           ALS in a clinically significant and measurable way

        2. Assessment of the impact of human neural stem cells transplantation on mortality (all
           causes)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      18 patients diagnosed as definite ALS according to the El Escorial criteria will be recruited
      during two years. The patients will be divided into 3 groups with different severity. Each
      group will be less compromised than the group that went before them. Their breathing
      measurements must be at least 60%. Subjects will receive injections of the human foetal
      neural stem cells into the spinal cord. A variety of tests and examinations will take place
      every month for the first year and every three months for the next two in order to monitor
      the course of the disease and the adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of a microsurgery human neural stem cells transplantation into spinal cord of ALS patients</measure>
    <time_frame>Participants will be followed for at least 3 years. Monthly in the first year and every three months the following two years</time_frame>
    <description>Percentage of subjects (%) with treatment-related mortality defined as death due to procedure and not to the course of the disease
Number of adverse events related to the procedure
Changes in neuroradiological (MRI) and neurophysiological variables (SEP, MEP)
Changes in neuropsychological variables</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Human Neural Stem Cells Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50,000 cells/µl. Patients received either unilateral or bilateral hNSCs microinjections (3 microinjections on each side) into the lumbar spinal cord. Each microinjection consisted of 15 µl of the above 50,000cells/µl suspension, yielding a total of 750,000 cells per injection site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Neural Stem Cells</intervention_name>
    <description>Surgical microinjection of human neural stem cells on spinal cord of ALS patients</description>
    <arm_group_label>Human Neural Stem Cells Suspension</arm_group_label>
    <other_name>Human Neural Stem Cells Suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of definite or possible ALS according to revised EL Escorial criteria

          -  Age: 20-75 years

          -  documented progression of disease during the last 6 months.

          -  Absence of concomitant diseases

          -  Adequate assurances of adherence to protocol

          -  The patient must be able to communicate verbally or with the use of non-verbal
             communication system

        Group 1

          -  maximum score of 1 on walking item of ALS functional rating scale

          -  forced vital capacity &gt; or equal to 60

        Group 2

          -  forced vital capacity &gt; or equal to 60

          -  ambulation difficulties (maximum score of 2 on walking item of ALS functional rating
             scale)

        Group 3

          -  Independent ambulation (score 4 on a scale ALS-FRS)

          -  forced vital capacity &gt; or equal to 70

        Exclusion Criteria:

        The presence of at least one of the following will lead to patient exclusion.

          1. psychiatric diseases or other neurological diseases different from ALS

          2. other systemic diseases

          3. Neoplasms or other diseases reducing life expectancy

          4. Antecedent polio infection

          5. corticosteroids, immunoglobulin or immunosuppressive treatment

          6. involvement in other clinical trials

          7. 2 or more critical items in MMPI

          8. neuropsychological evaluation suggestive of mental deterioration or cognitive sphere
             disturbance.

          9. Impediments to MRI

         10. patients unable to understand informed consent form and study aims.

         11. women who are pregnant or childbearing potential for the duration of the study.
             Non-pregnant status will be documented by beta-HCG negative test 7 days before
             treatment start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo L Vescovi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Casa Sollievo della Soffernza and AOSP Terni, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.revertonlus.org/</url>
    <description>No profit Association that grant this study</description>
  </link>
  <reference>
    <citation>Gelati M, Profico D, Projetti-Pensi M, Muzi G, Sgaravizzi G, Vescovi AL. Culturing and expansion of &quot;clinical grade&quot; precursors cells from the fetal human central nervous system. Methods Mol Biol. 2013;1059:65-77. doi: 10.1007/978-1-62703-574-3_6.</citation>
    <PMID>23934834</PMID>
  </reference>
  <results_reference>
    <citation>Mazzini L, Gelati M, Profico DC, Sgaravizzi G, Projetti Pensi M, Muzi G, Ricciolini C, Rota Nodari L, Carletti S, Giorgi C, Spera C, Domenico F, Bersano E, Petruzzelli F, Cisari C, Maglione A, Sarnelli MF, Stecco A, Querin G, Masiero S, Cantello R, Ferrari D, Zalfa C, Binda E, Visioli A, Trombetta D, Novelli A, Torres B, Bernardini L, Carriero A, Prandi P, Servo S, Cerino A, Cima V, Gaiani A, Nasuelli N, Massara M, Glass J, Sorarù G, Boulis NM, Vescovi AL. Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med. 2015 Jan 27;13:17. doi: 10.1186/s12967-014-0371-2.</citation>
    <PMID>25889343</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Santa Maria, Terni, Italy</investigator_affiliation>
    <investigator_full_name>Angelo Luigi Vescovi</investigator_full_name>
    <investigator_title>Scientific Director of Laboratorio Cellule Staminali, Cell Factory e Biobanca AOSP di Terni, Scientific Director IRCCS Casa Sollievo della Sofferenza S.Giovanni Rotondo Italy</investigator_title>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>motor neuron disease</keyword>
  <keyword>stem cells</keyword>
  <keyword>safety</keyword>
  <keyword>ALS-FRS-Functional scale R and FVC (%) variation</keyword>
  <keyword>Survival analysis</keyword>
  <keyword>Changes in quality of life scales</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

